No Data
Allogene Therapeutics (ALLO) Down 13.9% Since Last Earnings Report: Can It Rebound?
Allogene Therapeutics(ALLO.US) Director Sells US$26,181.12 in Common Stock
$Allogene Therapeutics(ALLO.US)$ Director Humer Franz B sold 11,200 shares of common stock on May 30, 2024 at an average price of $2.3376 for a total value of $26,181.12.Source: Announcement What is s
Express News | Allogene Therapeutics: Under Share Exchange Agreement, Jv Company Acquired From Overland 100% Equity Interest in Overland Pharmaceuticals (US) Inc
Express News | Allogene Therapeutics Inc: On May 24, Co, Overland Pharmaceuticals, Allogene Overland Biopharm Entered Into a Share Exchange Agreement
Allogene Therapeutics Initiated at Overweight by Piper Sandler
Allogene Therapeutics Initiated at Overweight by Piper Sandler
Piper Sandler Initiates Coverage On Allogene Therapeutics With Overweight Rating, Announces Price Target of $11
Piper Sandler analyst Biren Amin initiates coverage on Allogene Therapeutics (NASDAQ:ALLO) with a Overweight rating and announces Price Target of $11.